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Abstract
Background: There are limited data on the prevalence of multi-drug resistant tuberculosis (MDR-TB), estimated at
0.6-6.7%, in African children with tuberculosis. We undertook a retrospective analysis of the prevalence of MDR-TB
in children with Mycobacterium tuberculosis (MTB) at two hospitals in Johannesburg, South Africa.
Methods: Culture-confirmed cases of MTB in children under 14 years, attending two academic hospitals in
Johannesburg, South Africa during 2008 were identified and hospital records of children diagnosed with drug-
resistant TB were reviewed, including clinical and radiological outcomes at 6 and 12 months post-diagnosis.
Culture of Mycobacterium tuberculosis complex (MTB) was performed using the automated liquid broth MGIT™ 960
method. Drug susceptibility testing (DST) was performed using the MGIT™ 960 method for both first and second-
line anti-TB drugs.
Results: 1317 children were treated for tuberculosis in 2008 between the two hospitals where the study was
conducted. Drug susceptibility testing was undertaken in 148 (72.5%) of the 204 children who had culture-
confirmed tuberculosis. The prevalence of isoniazid-resistance was 14.2% (n = 21) (95%CI, 9.0-20.9%) and the
prevalence of MDR-TB 8.8% (n = 13) (95%CI, 4.8-14.6%). The prevalence of HIV co-infection was 52.1% in children
with drug susceptible-TB and 53.9% in children with MDR-TB. Ten (76.9%) of the 13 children with MDR-TB received
appropriate treatment and four (30.8%) died at a median of 2.8 months (range 0.1-4.0 months) after the date of
tuberculosis investigation.
Conclusions: There is a high prevalence of drug-resistant tuberculosis in children in Johannesburg in a setting
with a high prevalence of HIV co-infection, although no association between HIV infection and MDR-TB was found
in this study. Routine HIV and drug-susceptibility testing is warranted to optimize the management of childhood
tuberculosis in settings such as ours.
Background
Sub-Saharan Africa has a high burden of human immu-
nodeficiency virus (HIV) and Mycobacterium tuberculosis
(MTB) infection. Most of the 2.1 million HIV-infected
children live in sub-Saharan Africa including 10% in
South Africa [1]. An estimated 10% of the 2.9 million
new cases of tuberculosis in sub-Saharan Africa during
2007 occurred in children: 38% of all incident tuberculo-
sis cases in sub-Saharan Africa (regardless of age group)
were HIV-infected in 2007 [2]. Globally the prevalence of
multi-drug resistant tuberculosis (MDR-TB) in adults,
defined as resistance to at least isoniazid and rifampicin,
was estimated to be 4.6% in 2006 [3]. The prevalence of
MDR-TB in South African adults was 1.8% (1.4% - 2.3%)
amongst new treatment cases, and 6.7% (5.5% - 8.1%) in
previously treated individuals [3].
There are limited data on the prevalence of drug-resis-
tance in African children with tuberculosis. In Cape
Town, South Africa, between 2005 and 2007 the preva-
lence rates of MTB isoniazid resistance were 14.4% and
6.7% of isolates had MDR-TB [4]. These prevalence rates
had increased compared to one decade previously when
the prevalence of isoniazid resistance was 6.9% (95%
CI, 1.1-3.6) and MDR-TB 2.3% (95% CI, 0.9-6.6) [5].
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dren with MDR-TB in the study from Cape Town
between 2005 and 2007 [4]. In Bangui, Central Africa
Republic, although 15.2% of 165 children with culture-
confirmed tuberculosis in whom drug sensitivity testing
was available, had MTB strains resistant to at least one
drug, only one child (0.6%) had MDR-TB [6]. As children
with tuberculosis usually represent cases that have
recently acquired infection with MTB, they serve as a
crucial indicator of the drug-susceptibility patterns and
circulating strain diversity of MTB in a community [5].
The aim of this study was to review the prevalence
and clinical outcome of childhood MDR-TB at two hos-
pitals in Johannesburg, South Africa.
Methods
Study population and design
The study involved two secondary-tertiary care hospitals,
namely Chris Hani-Baragwanath Hospital (CHBH) and
Rahima Moosa Mother and Child Hospital (RMMCH) in
Johannesburg, South Africa. A retrospective analysis of
the laboratory data of children under 14 years of age with
microbiologically-confirmed tuberculosis, diagnosed
between 1
st January 2008 and 31
st December 2008, was
undertaken.
MTB microscopy, culture and susceptibility test
results from children treated at these two hospitals were
retrieved electronically from the National Health
Laboratory Service (NHLS) Mycobacteriology Referral
Laboratory in Johannesburg. DST was not performed
routinely on all TB suspects in 2008. Clinicians were
guided by the National TB Control Programme and it
was at the discretion of the clinician to request addi-
tional DST when requesting mycobacterial culture.
Thus, DST was only performed in the laboratory at the
clinician’s request.
Specimens submitted to the Mycobacteriology labora-
tory for mycobacterial culture with or without additional
DST were processed according to WHO guidelines
using the N-acetyl-L-cysteine-NaOH decontamination
procedure and the Auramine-O technique for direct
smear staining. Processed specimens were inoculated
into BACTEC™ Mycobacterial Growth Indicator Tube
(MGIT™) tubes (Becton-Dickinson, Sparks, Maryland,
USA) and incubated at 37°C for 6 weeks in automated
MGIT™ instruments. Acid fast bacilli in positive
MGIT™ culture tubes were identified as M. tuberculosis
complex by the HAIN GenoType
® Mycobacterium CM
assay. For those for whom DST was requested, they
would be initially tested against INH and rifampicin
using the MGIT™ 960 method. If resistance was found
against either or both of these drugs, the isolate would
undergo further DST against second line drugs (strepto-
mycin, ethambutol only in the case of INH mono-
resistance, or streptomycin, ethambutol, ethionamide,
kanamycin and ofloxacin in the case of rifampicin
mono-resistant MTB or MDR-TB) using the MGIT™
960 method. DST against pyrazinamide was performed
only if requested by the attending clinician. Blood speci-
mens were inoculated at the bedside into BACTEC™
Myco/F Lytic medium and these bottles were incubated
for 6 weeks in automated BACTEC™ 9240 incubators
in the laboratory. Identification of MTB or M.avium
complex from positive for AFB-blood cultures was by
nucleic acid probe (Accuprobe, Genprobe). DST on
MTB -positive blood cultures was also by the MGIT™
960 method after subcultirung the isolate from blood
into a MGIT™ tube.
MTB susceptibility was categorized as susceptible
based on isoniazid and rifampicin susceptibility (no
further DST testing against other drugs was performed
in these cases); isoniazid mono-resistance if resistant to
isoniazid only; rifampicin mono-resistance if resistant to
rifampicin only; MDR-TB when resistance to both
isoniazid and rifampicin was present; and extensively
drug-resistant (XDR-TB) when resistance to isoniazid,
rifampicin, a fluoroquinolone and kanamycin was present.
Children diagnosed with MDR-TB at either of the
hospitals were referred to Sizwe Hospital, a dedicated
MDR-TB treatment facility in Johannesburg. The stan-
dard of care for HIV-infected children at the study sites
during 2008 included highly active antiretroviral treat-
ment (HAART) and co-trimoxazole prophylaxis based
upon South African Department of Health guidelines
[7]. Additionally, the standard of care for children with
MDR-TB admitted to Sizwe Hospital included treatment
with pyrazinamide, ethionamide, ethambutol, amikacin
and ofloxacin in the intensive phase of treatment with
the addition of terizidone and/or kanamycin if additional
resistance patterns were present. Continuation phase
MDR-TB treatment consisted of ethionamide, ethambu-
tol and ofloxacin [8].
HIV status was ascertained by searching the laboratory
database for HIV DNA PCR results in children
<18 months, or HIV ELISA results in children ≥18 months
of age. Children were recorded as being HIV-infected,
HIV-uninfected or HIV unknown. CD4+ counts and HIV
viral load by PCR quantification, undertaken within three
months of the date when the child was investigated for
tuberculosis, were extracted for HIV-infected children.
‘Baseline’ was defined as the date when positive samples
had been submitted for investigation of tuberculosis.
A clinical-record review was performed for children
who had drug-resistant MTB, and the following data
recorded: baseline weight-for-age z-scores; clinical data
indicative of symptomatic tuberculosis at the time of
submission of the specimen from which MTB was cul-
tured; antituberculosis treatment history; tuberculosis
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died, or lost to follow-up). A 3-month period either side
of baseline was allowed for the collection of clinical
data. Additionally, for HIV-infected children, World
Health Organization (WHO) clinical stage and details of
HAART as well as response to HAART were recorded.
Time from tuberculosis diagnosis and initiation of anti-
tuberculosis treatment was calculated based on subject
record review or information received from the City of
Johannesburg Tuberculosis Program. Six- and 12-month
clinical and radiological data were recorded where
available.
Statistical analysis
The overall prevalence of drug-resistant MTB for case
isolates (number of childrenw i t hc u l t u r e - c o n f i r m e d
tuberculosis) in which MTB complex was cultured and
used as a denominator was calculated using the chi
square test with exact binomial 95% confidence intervals
(95%CI), or Fisher’s exact test, as appropriate. Preva-
lence of drug-resistant TB was also calculated using
only TB episodes (number of children with drug-resis-
tant tuberculosis) in which drug resistance testing was
undertaken as a denominator. Statistical analyses were
performed using STATA version 11.0 software (Stata-
Corp, College Station, Texas, USA). All tests were con-
ducted at a significance level of 0.05.
Ethics approval
Ethics approval was granted by the Human Research
Ethics Committee (Medical) of the University of the Wit-
watersrand. A waiver for informed consent on the part of
identified subjects was granted by the Ethics Committee
in accordance with this being a retrospective review.
Results
Drug susceptibility testing
In 2008, 1317 children were treated for tuberculosis
between the two hospitals based on information
accessed through an electronic register which is main-
tained at both facilities’ TB Focal Points.
MTB complex were cultured from 240 children in
2008, including 36 (15.0%) isolates that were considered
to be possible Mycobacterium bovis bacillus Calmette-
Guérin (BCG) strain, based on being exclusively identi-
fied from lymph node aspirates. Of these specimens,
seven demonstrated drug- resistant TB complex, all
from right axillary lymphadenitis (1 MDR-TB, 5 INH
mono-resistance and 1 INH poly-resistance (INH and
pyrazinamide). Pyrazinamide resistance patterns were
only available for the one lymph node isolate which
demonstrated pyrazinamide resistance.MTB speciation
was only undertaken (on clinician request) in one of
these 36 isolates, which was confirmed as M. bovis-BCG.
As it was not possible to ascertain retrospectively
whether isolates obtained from lymph node aspirates
were BCG in all cases, children in whom MTB complex
was only identified from lymph node aspirate samples
were excluded from further analysis as bias may have
been introduced by including these cases: ages were not
available for all children, and the location of lymph
node aspiration was not available for drug-sensitive
cases. (Figure 1). Two hundred and four children had
culture-confirmed tuberculosis; sites of identification of
the isolates from these 204 children included gastric
aspirates (n = 95; 46.6%), sputum (n = 75; 36.8%), blood
(n = 16; 7.8%), cerebrospinal fluid (n = 5; 2.5%), tracheal
aspirate (n = 5; 2.5%), pleural fluid (n = 4; 2.0%), bone
marrow (n = 1; 0.5%), synovial fluid (n = 1; 0.5%), tissue
(n = 1; 0.5%) and urine (n = 1; 0.5%). Only one positive
specimen was included per child and all duplicates were
removed from analysis. Drug susceptibility testing, at
the discretion of the attending clinician was conducted
on samples from 148 (72.5%) of the 204 children.
HIV prevalence in the cohort
Ninety- nine (48.5%; 95% CI, 41.5 to 55.6%) of the 204
children with culture-confirmed tuberculosis were HIV-
infected, 77 (37.7%; 95% CI, 31.1 to 44.8%) were HIV-
uninfected and the HIV infection status was unknown
in the remaining 28 (13.7%; 95% CI, 9.3 to 19.2%) chil-
dren. Baseline immunological results were available for
91 (91.9%) of the HIV-infected children (Table 1). The
median absolute CD4+ cell count was 312 cells/μl
(Interquartile Range [IQR], 113 to 743) and the median
CD4+ percentage, 17.5% (IQR, 8.5 to 23.2%). Baseline
viral loads were available for 87 (87.9%) HIV-infected
children, with a median of 4.60 log10 viral copies/ml
(IQR, 1.98 - 5.28). The CD4+ cell count and HIV viral
load of the HIV-infected population did not differ with
respect to those in whom drug susceptibility testing was
undertaken. Information regarding access to HAART
was limited as our data were laboratory-based and folder
reviews were only conducted for those children with
drug-resistant tuberculosis. Of the seven HIV-infected
children with MDR-TB, six were on HAART, and three
of these had failed first-line HAART regimens, and were
being treated with second line HAART regimens.
Drug susceptibility testing
Among the 148 isolates in which drug susceptibility
testing was undertaken, 23 (15.5%: 95% CI, 10.1 - 22.4%)
exhibited non-susceptibility to at least one first-line anti-
tuberculosis drug. The overall prevalence of isoniazid
resistance was 14.2% (95% CI, 9.0 to 20.9%; n = 21) and
rifampicin-resistance was 10.1% (95% CI, 5.8 to 16.2%; n
= 15). Isoniazid mono-resistance was prevalent in seven
(4.7%; 95% CI, 1.9 to 9.5%) cases and the isolate from one
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Figure 1 Children with culture positive TB- drug susceptibility patterns.
Table 1 Comparison of drug susceptible and drug resistant cases at baseline
Drug susceptible TB MDR TB Rifampicin mono-resistance INH Resistance with no
Rifampicin resistance
Number of children with positive
cultures submitted for DST
125 13 2 8
HIV infected 64 (51.2%) 7 (53.8%) 1 (50.0%) 6 (75.0%)
HIV uninfected 42 (33.6%) 6 (46.2%) 1 (50.0%) 2 (25.0%)
HIV unknown 19 (15.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Baseline CD4+ count 351 (126 - 825) 180 (36 - 264) 107 467 (246 - 831)
(median, IQR)
Baseline CD4 percentage (median, IQR) 17.2 (8.2 - 23.0) 14.2 (2.2 - 23.2) 5.3 28.2 (14.6 - 40.4)
Baseline log HIV Viral load (median, IQR) 4.49 (2.34 - 5.26) 5.19 (4.11 - 5.52) 4.67 3.17 (1.40 - 4.66)
Age months 24 (12 - 72) 25 (5 - 84) 78 (48 - 108) 60 (7 - 114)
(median, IQR)
Weight for age z-score Not available -2.8 (-3.5- -0.5) -2.2 (-3.1- -1.3) -2.0(-4.8- -0.2)
(median, range)
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ethambutol poly-resistance. In addition, two (1.4%; 95%
CI, 0.2 - 4.8%) cases were associated with rifampicin
mono-resistance. The overall prevalence of MDR-TB (n =
13) was 8.8% (95% CI, 4.8 to 14.6%) in isolates in which
drug susceptibility testing was undertaken.
MDR-TB episodes
There was no difference in the prevalence of HIV
between children with drug-susceptible tuberculosis and
those with MDR-TB (p = 0.771) (Table 1). Additionally,
there were no significant differences in age, CD4+ per-
centage, absolute CD4 count, or HIV log10 viral load
between HIV-infected children with MDR-TB compared
to those with drug-susceptible tuberculosis. The 13 chil-
dren with MDR-TB included eight children with concur-
rent streptomycin resistance, four with concurrent
ethambutol resistance and one child with ethionamide
resistance (Table 2). Only four (30.8%) of the 13 children
with MDR-TB were known to have been in contact with
adult tuberculosis cases. The median age of children with
positive TB contacts was 60.9 months (range 18.5-144
months). None of these adult contacts were admitted to
the MDR-TB treatment facility or were known to have
had drug susceptibility testing done on their MTB iso-
lates. One of the contacts of a child with MDR-TB was
Table 2 Baseline characteristics of children with MDR TB
Age
(m)
Sex TB
previous
TB
contact
Baseline
Clinical
HIV ART at
baseline
(m)
CD4 #
baseline
CD4%
baseline
RNA
PCR
baseline
Time to
appropriate
treatment (m)
WAZ-
score
Drug
Resistance
12 F N oN oaExprem,
CLD
Neg LTFU
$ -3.1 MDR
2 3.4 M No No aaExprem,
CDH,CLD,
ASD
Neg Died 3 days after
investigation
-3.9 MDR
3 3.8 M No No Well Neg 4.0 -0.5 MDR,
Strep
4 5.2 M No No WHO IV
Marasmus
Pos 2 2.0 -1.8 MDR
5 11.9 M No No Kwashiorkor Neg 3.3 -3.0 MDR
6 18.5 M No Yes
mom
defaulted
Kwashiorkor Neg 4.5 -2.0 MDR,
Strep
7 25 M No Yes
(father)
WHO IV
Kwashiorkor
Pos No
(Defaulted)
264 23.2 4.9 15 -2.3 MDR,
Strep
8 29.2 F No Unk UWFA Neg 3 -3.2 MDR
Strep
9 62 F no no WHO IV Pos 1 381 23.2 6.3 0.8 -3.5 MDR
10 83.7 F Yes 2001
and
2002
and
2008 ∞
U WHO IV
CLD
Pos 1
st line 23
m. 2nd line
regimen 4
m. Poor
adherence
105 5.1 1.4 0.3 -3.5 MDR,
EMB,
Strep
11 96.7 F No Yes WHO IV Pos Yes 36 m
Defaulter
9 1.1 5.1 1.3 -2.7 MDR,
Strep,
EMB
12 144 F Yes
2001,
2005,
2007 ^
Yes
mom
demised
from TB
2004
WHO III Pos 11 m 1
st
line Poor
adherence
2nd line
regimen 15
months
254 32 4.1 2.5 -1.0 MDR,
EMB,
Strep
13 144 M No U WHO IV Pos 2 36 2.2 5.5 1.5 -2.4 MDR,
Strep,
Eth,
EMB
Median 24 180 14.2 5.19 2.5 -2.8
a Ex-premature infant, CLD= chronic lung disease.
aa CHD=Congenital diaphragmatic hernia, ASD=Atrial septum defect.
$ LTFU= Lost to follow up.
^ Resistant to ethambutol and isoniazid: treated with ethionamide and ciprofloxacin.
∞ Admitted to MDR-TB Hospital.
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the known contact of another had demised.
Management of children with MDR-TB
Two (15.4%) children with MDR-TB received no antitu-
berculosis treatment, including one child who died and
one child who defaulted follow-up. A third child who
received two months of empiric therapy for drug sus-
ceptible tuberculosis, and then defaulted care was
recalled and re-investigated by attending physicians
15 months after the initial investigation revealed MDR-
TB. The repeat MTB cultures in this child were negative
and based on the child being clinically well with a nor-
mal chest radiograph, the attending physician opted not
to initiate MDR-TB treatment.
Ten (76.9%) of the 13 children with MDR-TB
received appropriate anti-tuberculosis treatment. The
median time to tracing and initiation of appropriate
anti-tuberculosis treatment from time of specimen
submission in these children was 2.5 months (range
0.3-15 months). Seven children (53.8%) with MDR-TB
and one child with rifampicin-resistant tuberculosis
were started on first-line antituberculosis treatment
initially. Two of the 13 children were started on MDR-
TB treatment within one month of specimen submis-
sion, both of whom were diagnosed with MDR-TB
based on the line probe assay.
Seven children were admitted to the MDR-TB treat-
ment facility for further management for a median time
period of 6.0 months (range 3 - 17 months). Three chil-
dren were treated at the study-hospitals with MDR-TB
treatment regimens as they were too unstable for refer-
ral to the MDR treatment-facility.
Outcome of children with MDR-TB
Four children (30.8%) with MDR-TB died at a median of
2.8 months (range 0.1-4.0 months) from the time when
the initial sample identifying MDR-TB was submitted.
This included three HIV-infected children on HAART
who had been initiated on MDR-TB treatment at a
median time of 1.5 months after sample submission for
mycobacterial culture. These three children were treated
in the study-hospitals as they were too unstable for
down-referral to the MDR-TB treatment facility. The
fourth child, an HIV-uninfected two-month old, was an
ex-premature infant with an atrial septal defect, conge-
nital diaphragmatic hernia and chronic lung disease.
This child died within three days of specimen submis-
sion and was not initiated on anti-tuberculosis treat-
ment. One of the children who died had MDR-TB
meningitis and the other three children died from severe
pneumonia. There was no correlation between weight
for age z-scores and death.
At 12-month follow-up (table 3) the mean weight-for-
age z-score was -1.6 (range -3.1 to 0.4) in the nine survi-
vors. In three HIV-infected children in whom follow-up
results were available, the median CD4+ count was 291
cells/μl (range 285 - 2050 cells/μl) with a median CD4+
percentage of 16.4% (range 11.1 - 33.0%). The median
HIV viral load was 4.7 log10 copies/ml (range 1.4 - 5.0).
One child had worsening changes on chest radiograph.
All other children with severe chest radiographic
changes at baseline were noted to have improved by
12 months. All children who had been admitted to the
MDR-TB treatment facility were retained in care, with
none defaulting treatment follow-up. There were no
deaths between the 6 and 12-month follow up periods.
Table 3 12 month outcomes of children with MDR TB
Baseline 12-month follow-up
Age (m) Sex HIV Outcomes WAZ-score CD4 # CD4% WAZ-score CD4 # CD4% RNA
1 2 F Neg Lost to follow-up -3.1
2 3.4 M Neg Died 0.1 m -3.9
3 3.8 M Neg *MTBH 3 m -0.5 -1.6
4 5.2 M Pos Died 4.0 m -1.8
5 11.9 M Neg MTBH 6 m -3 -0.4
6 18.5 M Neg MTBH 6 m -2 -0.9
Traced
7 25 M Pos Re-investigated -2.3 264 23.2 -3.1 297 21.7 5
8 29.2 F Neg MTBH 6 m -3.2 -2
9 62 F Pos MTBH 7 m -3.5 381 23.2 -0.9
10 83.7 F Pos MTBH 17 m -3.5 105 5.1 -2.1 285 11.1 4.7
11 96.7 F Pos Died 1.8 m -2.7 9 1.1
12 144 F Pos MTBH 12 m -1 254 32 -1.6 513 14.4 2.9
13 144 M Pos Died 4.0 m -2.4 36 2.2
*MTBH= MDR TB treatment facility.
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This study demonstrates a high prevalence of MDR-TB
in children in Johannesburg, South Africa. MDR-TB
prevalence of 8.8% in cases on which drug-susceptibility
testing was performed in our study are higher than the
point-prevalence of MDR described in other African
paediatric studies (2.3-6.7%) [4-6]. Drug resistant-tuber-
culosis was prevalent in 16% of children with culture-
confirmed tuberculosis, whose specimens underwent
susceptibility testing. Notably, only four of the children
with MDR-TB had a known exposure to an adult tuber-
culosis contact, none of whom were diagnosed with
MDR-TB. Contact tracing in our context is poorly per-
formed; a study at three Johannesburg academic hospi-
tals (including CHBH and RMMCH) showed that 15%
of 113 severely malnourished paediatric inpatients had
contact with an adult recently diagnosed with tuberculo-
sis, and none were offered IPT [9]. Lack of MDR-TB
household contacts in our cohort suggests transmission
outside the home, but further epidemiologic patterns
could not be ascertained. As childhood tuberculosis is a
marker of ongoing adult disease and MTB transmission,
our study suggests that MDR-TB transmission occurred
within the community as well as within the child’s
household [10-12]. As childhood tuberculosis also serves
as a measure of the drug-susceptibility patterns of MTB
being transmitted within a community, our study indi-
cates that there is a high prevalence of MDR-TB circu-
lating in our setting.
High rates of drug-resistant MTB may impact on
tuberculosis preventive therapy strategies that have
recently been recommended in the South African
national TB guidelines (2009) [13]. In children with
INH mono-resistance or poly-resistance, without rifam-
picin resistance, 75% were HIV infected. The high pre-
valence of isoniazid resistance (14.2%; 95% CI, 9.0 to
20.9%) demonstrated in our study raises questions about
the effectiveness of isoniazid preventive therapy in our
community [14]. The high prevalence of isoniazid resis-
tance in this setting may also, in part, explain the lack
of efficacy of primary isoniazid prophylaxis in improving
tuberculosis-free survival in HIV-infected children in
our setting [15].
Current South African tuberculosis guidelines (2009)
[13] recommend tuberculosis microscopy and culture in
adult tuberculosis suspects with smear-negative disease
who are ill and not responding to antibiotics, regardless
of HIV status. No drug susceptibility testing is recom-
mended for smear-positive adult cases. One specimen
for MTB culture and sensitivity is sent for high-risk TB
suspects [13]. In child tuberculosis suspects, smear and
culture of sputum or gastric aspirates is recommended,
and paediatric studies have demonstrated that it is pos-
sible to perform these investigations in many settings, in
children of varying ages; however they are often not
done routinely in outpatient settings [16,17]. Currently,
drug susceptibility testing is not routinely performed on
MTB isolates cultured from children and drug suscept-
ibility testing of isolates in children with tuberculosis in
our cohort was performed at clinician discretion in an
academic hospital setting, deviating from current
local guidelines [13]. Line probe assays have been
demonstrated to provide drug susceptibility results within
5 - 7 days in high-throughput laboratories in microscopy-
positive specimens, or once MTB is cultured; [18] this
test still requires evaluation in specimens derived from
children. Future plans nationally in South Africa are
to enhance the capacity for routine testing of all smear-
positive adult and paediatric specimens using this assay,
in order to report drug sensitivity patterns more rapidly.
High MDR-TB attributable mortality (30.8%) was evi-
dent in our cohort at a median of 2.8 months after
investigation. Of the children who demised, three were
HIV-infected on HAART and the fourth child was an
HIV-uninfected ex-premature infant with associated
congenital abnormalities. The three children who
demised and were started on MDR treatment, started
MDR-TB therapy at a median of 1.5 months after speci-
men submission, demonstrating no significant delay in
access to specific therapy compared to the survivors.
This mortality is higher than described in a previous
study from the Western Cape where 10% of children
with MDR-TB died over a four year study period, 50%
of whom were HIV-infected; [19] and compared to 3.5%
d e s c r i b e di nc h i l d r e nw i t hc u l t u r e - c o n f i r m e dM D R - T B
receiving community based treatment in Lima, Peru
[20]. In our study, one child died of MDR-TB meningitis
and the other three children died of pneumonia and
acute respiratory failure. All children died in hospital as
they were too unstable to be transferred to a MDR-TB
treatment facility. Appropriate isolation facilities are not
widely available in many general hospital settings in
South Africa, and therefore these children constituted
an infection control dilemma when known to have
MDR-TB, as well as prior to their MDR-TB diagnoses.
Even if the diagnosis of MDR-TB is expedited through
modern diagnostic techniques, increased risk of nosoco-
mial MDR-TB transmission to fellow patients and
healthcare workers is likely if adequate isolation facilities
are not available [21]. With increased MDR-TB rates
evident especially in high HIV prevalence areas, infec-
tion control needs to be addressed urgently.
Our study has limitations, including the fact that we
may have overestimated the true MDR-TB prevalence in
children in Johannesburg, as patients attending referral
hospitals may be at higher risk for drug-resistant tuber-
culosis compared to those investigated and treated at pri-
mary care facilities. In the Western Cape (2003 - 2005),
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Page 7 of 9however, there was no difference in drug susceptibility
patterns between MTB isolates from hospitalized com-
pared to community-based childhood TB cases [5].
Furthermore, in our study, DST was performed in only
72.5% of children with culture-confirmed tuberculosis at
clinician discretion, which may have introduced some
bias. Our analysis also excluded all specimens with cul-
ture-confirmed mycobacterial isolates derived from
lymph node aspirates, in order to control for the possibi-
lity of drug resistance being associated with culture of M.
bovis-BCG [22,23] which is innately resistant to pyrazina-
mide and variably resistant to isoniazid [24-26]. Drug
susceptibility testing against pyrazinamide is not routi-
nely performed in our setting and is only performed on
clinician request. As we only had pyrazinamide resistance
patterns for one specimen, we could not make any
assumptions about whether these lymph node isolates
were M.bovis or M.tuberculosis based on pyrazinamide
resistance. As the study was retrospective and record-
based, contact history data may be inaccurate. Detailed
data on children with drug-susceptible MTB was not
available for this study, as information was collected from
laboratory records.
This study reports MTB and MDR-TB/HIV co-infec-
tion rates in the HAART era. In our cohort there were
high rates of HIV co-infection. There was, however, no
difference in HIV co-infection prevalence between chil-
dren diagnosed with drug-susceptible and MDR-TB
(P = 0.771), suggesting that HIV infection does not
appear to be a risk factor for MDR-TB in this setting.
There was also no significant difference between abso-
lute CD4+ count, CD4+ percentage and HIV viral load
in drug-susceptible and MDR-TB cases. Our study find-
ings, nevertheless, highlight the importance of ascertain-
ing the HIV-infection status of every child diagnosed
with tuberculosis.
Conclusion
In conclusion, we have demonstrated a high prevalence
of drug-resistant MTB in a cohort of children diagnosed
with culture-confirmed tuberculosis in Johannesburg,
South Africa; this likely represents a large burden of
undiagnosed drug-resistant MTB in household and
community adult contacts of these children. All child
tuberculosis suspects in settings with a high prevalence
of tuberculosis and HIV should have confirmation of
their HIV infection status. Furthermore, we recommend
that routine DST should be performed on MTB isolates
obtained from children with culture-confirmed TB in
these high-burdened settings.
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